LONP1 facilitates pulmonary artery smooth muscle cell glycolytic reprogramming by degrading MPC1 in pulmonary hypertension
Clinical Science · 2025
DOI: 10.1042/cs20255922 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Science, 2025. Verfasst von Mingkang Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongda Hospital, Southeast University, 87 Dingjiaqiao, Nanjing, Jiangsu 210009, China. Hauptthemen laut MEDLINE: Pulmonary Artery, Glycolysis, Myocytes, Smooth Muscle, Hypertension, Pulmonary. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Provincial Medical Key Discipline (Laboratory).
Abstract (Originalsprache)
Pulmonary hypertension (PH) is a chronic and life-threatening disease characterized by pulmonary vascular remodeling (PVR), which involves the abnormal proliferation of pulmonary artery smooth muscle cells (PASMCs). These cells exhibit metabolic characteristics akin to cancer cells, particularly in their shift toward glycolysis. The Lon protease 1 (LONP1) has been shown to promote glycolytic reprogramming of tumor cells, conferring a malignant proliferative phenotype. However, the precise role of LONP1 in PH remains unclear. In the present study, Su5416/hypoxia-induced and monocrotaline (MCT)-induced PH rodent models and platelet-derived growth factor BB (PDGF-BB)-induced PASMCs were used to investigate the role and mechanism of LONP1 in PH. The results revealed an up-regulation of LONP1 expression in lung tissues from two PH rodent models, as well as in PDGF-BB-induced PASMCs. In vivo knockdown of LONP1 significantly alleviated PASMC mitochondrial dysfunction, reduced glycolytic enzyme expression, and decreased lactate accumulation, thereby mitigating PVR. Additionally, in vitro experiments demonstrated that knockdown or inhibition of LONP1 attenuated glycolytic reprogramming, proliferation, and migration of PASMCs, whereas overexpression of LONP1 had converse effects. Mechanistic studies confirmed that mitochondrial pyruvate carrier 1 (MPC1) was a direct substrate for LONP1-mediated degradation. Functional experiments with MPC1 knockdown and overexpression further elucidated its role in the proliferation and migration of PASMCs. Rescue experiments indicated that MPC1 knockdown abrogated the suppressive effects of LONP1 knockdown on glycolytic reprogramming, proliferation, and migration in PASMCs. Therapeutically, knockdown or pharmacological inhibition of LONP1 significantly reversed MCT-induced PH in rats. Thus, targeting LONP1 may represent a promising therapeutic strategy for PH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Zhongda Hospital, Southeast University, 87 Dingjiaqiao, Nanjing, Jiangsu 210009, China.
- School of Medicine, Southeast University, Nanjing, Jiangsu, China.
- Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.
ORCID-Profile: Mingkang Li, Chengchun Tang
Förderung
- National Natural Science Foundation of China
- Jiangsu Provincial Medical Key Discipline (Laboratory)
Zitieren
APA
Li, M., Zhang, W., Zhang, M., Li, L., Yao, Y., Qin, Y., Wang, D., Yan, G., Qiao, Y., & Tang, C. (2025). LONP1 facilitates pulmonary artery smooth muscle cell glycolytic reprogramming by degrading MPC1 in pulmonary hypertension. Clinical Science. https://doi.org/10.1042/cs20255922
Vancouver
Li M, Zhang W, Zhang M, Li L, Yao Y, Qin Y, et al. LONP1 facilitates pulmonary artery smooth muscle cell glycolytic reprogramming by degrading MPC1 in pulmonary hypertension. Clinical Science. 2025. doi:10.1042/cs20255922
BibTeX
@article{Li2025,
author = {Li, Mingkang and Zhang, Wenkang and Zhang, Minhao and Li, Linqing and Yao, Yuyu and Qin, Yuhan and Wang, Dong and Yan, Gaoliang and Qiao, Yong and Tang, Chengchun},
title = {LONP1 facilitates pulmonary artery smooth muscle cell glycolytic reprogramming by degrading MPC1 in pulmonary hypertension},
journal = {Clinical Science},
year = {2025},
doi = {10.1042/cs20255922}
}
EUVIMED